CVRx Inc
NASDAQ:CVRX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
CVRx Inc
NASDAQ:CVRX
|
173.9m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.4B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.5B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.1B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.4B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39.2B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for CVRx Inc is -93%, which is above its 3-year median of -118.3%.
Over the last 3 years, CVRx Inc’s Net Margin has increased from -218.7% to -93%. During this period, it reached a low of -218.7% on Sep 30, 2022 and a high of -93% on Sep 30, 2025.
